British Columbia Investment Management Corp Lowers stake in Amgen (AMGN)

Amgen (AMGN) : British Columbia Investment Management Corp reduced its stake in Amgen by 11.96% during the most recent quarter end. The investment management company now holds a total of 377,351 shares of Amgen which is valued at $62,006,316 after selling 51,247 shares in Amgen , the firm said in a disclosure report filed with the SEC on Oct 12, 2016.Amgen makes up approximately 0.63% of British Columbia Investment Management Corp’s portfolio.

Other Hedge Funds, Including , Ct Financial Advisors boosted its stake in AMGN in the latest quarter, The investment management firm added 550 additional shares and now holds a total of 14,481 shares of Amgen which is valued at $2,379,518. Amgen makes up approx 1.50% of Ct Financial Advisors’s portfolio.Raymond James Trust N.a. boosted its stake in AMGN in the latest quarter, The investment management firm added 289 additional shares and now holds a total of 37,127 shares of Amgen which is valued at $6,248,845. Amgen makes up approx 0.54% of Raymond James Trust N.a.’s portfolio. Stillwater Capital Advisors added AMGN to its portfolio by purchasing 1,215 company shares during the most recent quarter which is valued at $204,497. Amgen makes up approx 0.06% of Stillwater Capital Advisors’s portfolio.Indiana Trust Investment Management Co reduced its stake in AMGN by selling 45 shares or 2.01% in the most recent quarter. The Hedge Fund company now holds 2,189 shares of AMGN which is valued at $366,088. Amgen makes up approx 0.19% of Indiana Trust Investment Management Co’s portfolio. Curbstone Financial Management Corp added AMGN to its portfolio by purchasing 2,410 company shares during the most recent quarter which is valued at $403,048. Amgen makes up approx 0.13% of Curbstone Financial Management Corp’s portfolio.

Amgen closed down -3.99 points or -2.37% at $164.32 with 27,61,896 shares getting traded on Tuesday. Post opening the session at $167.82, the shares hit an intraday low of $163.51 and an intraday high of $167.82 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.